Financial Results

Key highlights

Filter

Period

Filter by

recent search

Reset

Showing: 1 – 05 of 23 Financial Results

Ipsen delivers encouraging sales growth in the first quarter of 2021 despite the pandemic, and confirms its full-year guidance
 –  22 April 2021

22 April 2021

Download
Ipsen delivers encouraging sales growth in the first quarter of 2021 despite the pandemic, and confirms its full-year guidance

Attachment


Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021
 –  11 February 2021

11 February 2021

Download
Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021

Attachment


Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance
 –  22 October 2020

22 October 2020

Download
Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance

Paris (France), 22 October 2020 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2020.


Ipsen presents its half year 2020 results and reinstates guidance for full year 2020
 –  30 July 2020

30 July 2020

Download
Ipsen presents its half year 2020 results and reinstates guidance for full year 2020

David Loew, Chief Executive Officer of Ipsen, stated: “I’m honored since July 1st to lead Ipsen, an exciting global biopharma business with solid business fundamentals, a strong purpose to serve patients and attractive growth opportunities. I am encouraged by the exceptional levels…


Ipsen reports solid sales growth in first quarter 2020 with limited COVID-19 impact
 –  22 April 2020

22 April 2020

Download
Ipsen reports solid sales growth in first quarter 2020 with limited COVID-19 impact

Paris (France), 22 April 2020 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced its sales for the first quarter of 2020.


1 2 3 4 5

Your dedicated contacts